Targets › TERC
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: the race on TERC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Åslaug Helland | UV1 vaccine Therapeutic cancer vaccine targeting telomerase (hTERT) to activate hTERT-specific T cells | TERC | Phase 2 | Cancer | Mar 2027 |
| Centre Hospitalier Universitaire de Besancon | UCPVax CD4 Th1-inducing cancer vaccine targeting telomerase | TERC | Phase 2 | Hepatocellular Carcinoma | Mar 2028 |
Cancer (1) Hepatocellular Carcinoma (1)
mixed (2)
Åslaug Helland (1) Centre Hospitalier Universitaire de Besancon (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.